Bioventus Stock Today
| BVS Stock | USD 11.71 0.20 1.74% |
Performance6 of 100
| Odds Of DistressOver 52
|
Bioventus is selling for under 11.71 as of the 24th of November 2024; that is 1.74 percent increase since the beginning of the trading day. The stock's lowest day price was 11.3. Bioventus has 52 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Bioventus are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of October 2024 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 11th of February 2021 | Category Healthcare | Classification Health Care |
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the bodys natural healing process in the United States and internationally. The company was founded in 2011 and is headquartered in Durham, North Carolina. The company has 65.37 M outstanding shares of which 1.34 M shares are currently shorted by investors with about 3.57 days to cover. More on Bioventus
Moving against Bioventus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Bioventus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Robert Claypoole | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Medical Equipment (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Vistry Group PLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, HNX 30, NASDAQ Composite, SPASX All Technology, HNX Large Cap, Australia All Ordinaries, HNX Financials, NASDAQ Health Care, Medical Equipment, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBioventus can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bioventus' financial leverage. It provides some insight into what part of Bioventus' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bioventus (BVS) is traded on NASDAQ Exchange in USA. It is located in 4721 Emperor Boulevard, Durham, NC, United States, 27703 and employs 1,030 people. Bioventus is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 765.46 M. Bioventus runs under Health Care Equipment & Supplies sector within Health Care industry. The entity has 65.37 M outstanding shares of which 1.34 M shares are currently shorted by investors with about 3.57 days to cover.
Bioventus has about 34.36 M in cash with 15.34 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56.
Check Bioventus Probability Of Bankruptcy
Ownership AllocationBioventus holds a total of 65.37 Million outstanding shares. Over half of Bioventus' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Bioventus Ownership Details
Bioventus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-06-30 | 487.3 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 390.2 K | |
| Renaissance Technologies Corp | 2024-09-30 | 387.9 K | |
| Oberweis Asset Management Inc | 2024-06-30 | 380.9 K | |
| Segall Bryant & Hamill | 2024-09-30 | 377.8 K | |
| Pura Vida Investments, Llc | 2024-09-30 | 352.6 K | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 332.3 K | |
| Northern Trust Corp | 2024-09-30 | 322.4 K | |
| D. E. Shaw & Co Lp | 2024-09-30 | 321.6 K | |
| Essex Woodlands Health Ventures | 2024-09-30 | 13 M | |
| Juniper Investment Co, Llc | 2024-09-30 | 6.9 M |
Bioventus Historical Income Statement
Bioventus Stock Against Markets
Bioventus Corporate Management
| Anthony JD | General VP | Profile | |
| Kenneth Reali | CEO Director | Profile | |
| MBA BS | Senior Operations | Profile | |
| Helen Leupold | Senior Officer | Profile | |
| Katrina Church | VP Officer | Profile | |
| Alessandraa Pavesio | VP Officer | Profile |
Additional Tools for Bioventus Stock Analysis
When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.